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E-mail address: dsacks@rics.bwh.harvard.edu (D.BThe IQGAP family comprises three proteins in humans. The best characterized is IQGAP1, which par-
ticipates in protein–protein interactions and integrates diverse signaling pathways. IQGAP2 and
IQGAP3 harbor all the domains identiﬁed in IQGAP1, but their biological roles are poorly deﬁned.
Proteins that bind IQGAP1 include Cdc42 and Rac1, E-cadherin, b-catenin, calmodulin and compo-
nents of the mitogen-activated protein kinase pathway, all of which are involved in cancer. Here,
we summarize the biological functions of IQGAPs that may contribute to neoplasia. Additionally,
we review published data which implicate IQGAPs in cancer and tumorigenesis. The cumulative evi-
dence suggests IQGAP1 is an oncogene while IQGAP2 may be a tumor suppressor.
 2009 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction
IQGAPs comprise a class of multidomain proteins, which are
present in diverse organisms ranging from yeast and Caenorhabdi-
tis elegans to Xenopus laevis and mammals [1]. There are three
IQGAPs in humans (Fig. 1). The ﬁrst to be described was the
190-kDa protein IQGAP1, which was cloned in 1994 [2]. IQGAP2,
which is 62% identical to IQGAP1, was identiﬁed 2 years later [3]
and IQGAP3 was isolated in 2007 [4]. The vast majority (>85%) of
the published literature focuses on IQGAP1. Less is known about
IQGAP2 (20 primary papers in PubMed [http://www.ncbi.nlm.nih.
gov/pubmed] at the time of writing) and there are only two pri-
mary papers on IQGAP3. The cytoskeletal [5–8] and cellular signal-
ing [1,9] functions of IQGAP1 have been extensively reviewed in
the last few years. Here, we brieﬂy compare the characteristics of
IQGAP1, IQGAP2 and IQGAP3, then focus on published data that
address their involvement in neoplasia.chemical Societies. Published by E
CK1, casein kinase 1; ECM,
r; ERK, extracellular signal-
, GTPase-activating protein;
ocellular carcinoma; MAPK,
e; MMP, matrix metallopro-
ctor
. Sacks).2. Comparison of human IQGAP proteins
The IQGAP proteins share a similar domain structure and have
considerable sequence homology (Fig. 1). These domains mediate
the association of IQGAPs with a diverse spectrum of proteins
[9]. Binding to IQGAP1 modulates the function of the interacting
proteins, resulting in the alteration of multiple cellular behaviors
[5,7,9]. Despite limited information on IQGAP2 and IQGAP3, it is
apparent that they differ from IQGAP1 in several respects (includ-
ing tissue distribution, subcellular localization and interaction with
binding proteins). These distinctions may account for some of the
functional differences among the three IQGAPs that are beginning
to emerge.
The tissue distribution of the IQGAP proteins varies consider-
ably. IQGAP1 has ubiquitous expression [2]. IQGAP2 is found pre-
dominantly in liver, but can be detected in prostate, kidney,
thyroid, stomach, testis, platelets and salivary glands [3,4,10,11],
while IQGAP3 is reported to be present in brain, lung, testis, small
intestine and colon [4,12].
IQGAPs exhibit both similarities and differences in their subcel-
lular localization. In human epithelial cells in culture, endogenous
IQGAP1 is distributed throughout the cytoplasm and accumulates
at cell–cell junctions where it co-localizes with E-cadherin [13].
In quiescent human platelets IQGAP2 demonstrates diffuse cyto-
plasmic staining [10]. When platelets are activated, IQGAP2 is
found predominantly in ﬁlopodia, with less prominent staining inlsevier B.V. All rights reserved.
Fig. 1. A schematic diagram of human IQGAP proteins. Domain structure (adapted from SMART and Pfam databases) and percentage amino acid identity of human IQGAP1,
IQGAP2 and IQGAP3 are shown. CHD, calponin homology domain; WW, poly-proline protein–protein domain; IQ, IQ domain (with four IQ motifs); GRD, RasGAP-related
domain; RasGAP_C, carboxy-terminal sequence found in members of the IQGAP family.
1818 C.D. White et al. / FEBS Letters 583 (2009) 1817–1824the cell body. By contrast, IQGAP2 is predominantly localized in the
nucleus and at sites of cell–cell contact in isolated rabbit gastric
glands in primary culture [14]. In this study, IQGAP1 was observed
to be targeted predominantly to the cortex of chief and mucous
neck cells. These ﬁndings contradict those of an earlier publication
where IQGAP1 and IQGAP2 were localized to the basolateral and
apical membranes, respectively, in rabbit gastric parietal cells
[15]. The localization of IQGAP3 in human cells has not been de-
scribed. In PC12 rat phaeochromocytoma cells IQGAP3 is diffusely
distributed in the cytoplasm [4], while in cultured Eph4 mouse epi-
thelial cells it is found at cell–cell junctions [12]. IQGAP1 and IQ-
GAP3 have similar distribution in the cell bodies, distal parts of
axons and axon growth cones of rat embryo hippocampal neurons
[4]. Interestingly, IQGAP3 expression is reported to be conﬁned to
proliferating cells [12]. Additional studies are necessary to clearly
delineate the subcellular distribution of IQGAP2 and IQGAP3 in hu-
man tissue.
3. IQGAP binding proteins
IQGAP1 binds numerous proteins [9]. Much less is known about
the binding partners of IQGAP2 and IQGAP3. Nevertheless, sufﬁ-
cient information is now available to permit one to begin to tease
out differences. IQGAP1 binds to GTP-Cdc42 and GTP-Rac1 with
substantially higher afﬁnity than to the inactive, GDP-bound form
of the GTPases [16,17]. Similarly, the interaction of IQGAP3 with
Rac1 and Cdc42 appears to be GTP-dependent [4]. In contrast,
although not observed in all cases [15], IQGAP2 has been reported
to interact with both the GDP- and the GTP-bound forms [3,18].
Another protein that may bind differentially to IQGAPs is Ras. No
interaction between H-Ras and IQGAP1 [16,18,19] or IQGAP2
[3,18] has been detected (IQGAP1 was identiﬁed in a complex with
M-Ras [20], but direct binding has not been demonstrated). For IQ-
GAP3, the evidence is contradictory. One group reported that Ras
binds to IQGAP3 [12], while other investigators failed to observe
an interaction between the two proteins [4]. Further work is re-
quired to reconcile these discrepant ﬁndings and provide detailed
analysis of the binding partners of IQGAP2 and IQGAP3.
It is important to emphasize that, despite the presence of a
domain with sequence similarity to RasGAPs, none of the IQGAPs
have GTPase-activating protein (GAP) activity. As mentioned,
IQGAP proteins bind to the Rho family GTPases Rac1 and Cdc42.
These proteins act as molecular switches by cycling between
‘‘on” GTP-bound and ‘‘off” GDP-bound states [21]. Interaction with
a GAP accelerates GTP hydrolysis leading to inactivation. By
associating with GTP-bound Rac1 and Cdc42, IQGAP1 and IQGAP2
inhibit the intrinsic rate of GTP hydrolysis and thus stabilize the
active GTP-bound state [3,16,22]. Consistent with these in vitro
ﬁndings, overexpression of IQGAP1 in MCF-7 malignant human
breast epithelial cells increases the amount of active Cdc42 and
Rac1 [22,23].In addition to regulating Rac1 and Cdc42 signaling, recent work
has shown that IQGAPs, and IQGAP1 in particular, modulate many
different signaling pathways and cellular functions [9], including
mitogen-activated protein kinase (MAPK) signaling, Ca2+/calmodu-
lin signaling, cell–cell adhesion, b-catenin-mediated transcription
and microbial invasion [9,24,25]. Ca2+ and calmodulin appear to
be of great importance to the function of IQGAP1. Calmodulin
binds to IQGAP1 in a Ca2+-regulated manner [16,17], and associa-
tion with calmodulin inhibits the ability of IQGAP1 to interact with
every other binding partner studied to date [1,9].
A ﬁnding with particular relevance to the topic of this review is
that many IQGAP1 binding partners have well-deﬁned roles in
tumorigenesis (Table 1). These proteins include the well-described
oncogenes b-catenin and Src, the tumor suppressor E-cadherin, the
Rho GTPases Cdc42 and Rac1, and components of the MAPK cas-
cade. These observations, in conjunction with the ability of IQGAP1
to modulate fundamental cellular functions, have led to consider-
able attention being directed towards IQGAP1 in the ﬁeld of cancer
biology. Work from several laboratories suggests that IQGAP1 is an
oncogene that promotes both tumorigenesis and metastasis and, to
a more limited extent, implies that it may be a useful tumor mar-
ker. IQGAP2, in contrast, appears to have the opposite effect and
may act as a tumor suppressor. Little can be inferred regarding
the possible role of IQGAP3 in neoplasia. Here, we review the avail-
able evidence for the involvement of IQGAPs in the regulation of
signaling pathways and cellular functions known to be involved
in neoplastic transformation and/or tumor progression. Addition-
ally, we discuss how, by virtue of their cellular expression and/or
localization, IQGAPs are directly implicated in cancer. While most
of the data presented are germane only to IQGAP1, we also discuss
the possible roles of IQGAP2 and IQGAP3 where published evi-
dence is available.
4. IQGAP functions with potential relevance to cancer
IQGAP1 regulates many different cellular processes, and chang-
ing intracellular IQGAP1 expression or function can alter these
activities [1,5,7,9]. Therefore, IQGAP1 appears to be important for
normal cellular function and homeostasis. The contribution of
some of these cellular activities to different stages of cancer pro-
gression provides a clear link between IQGAP1 and cancer. Selected
cell functions, and how the IQGAPs control them, will be described.
4.1. MAPK signaling
The MAPK pathway, which modulates multiple cellular pro-
cesses, such as differentiation, proliferation and migration, is
deregulated in neoplasia [26,27]. For example, mutations in Ras
[28] or B-Raf [29,30] are highly prevalent in neoplasms. Activating
mutations in Ras have been reported in over 15% of all human tu-
mors and in pancreatic carcinoma this frequency may be as high as
Table 1
IQGAP1 binding proteins with identiﬁed roles in cancer.
Binding
partner
Effect of IQGAP1 on target protein Functional consequence of interaction Potential relevance to cancer References
Arf6 Promotes Arf6-induced Rac1 activation Enhances cell migration Metastasis [70]
b-Catenin Promotes b-catenin-mediated transcription; inhibits
cell–cell adhesion
Disrupts cell–cell adhesion Transformation and metastasis [45,53,95]
B-Raf MAPK scaffold; increases B-Raf activity Enhances proliferation and angiogenesis Transformation [35,49]
Calmodulin Prevents interaction of IQGAP1 with other binding
proteins
Regulates IQGAP1 functions Proliferation and metastasis [16,17,96]
CD44 Links hyaluronan to actin cytoskeleton Promotes migration Metastasis [38]
Cdc42/Rac1 Stabilizes active form Promotes proliferation, cell motility and
invasion
Proliferation, invasion and
metastasis
[16,19,23,63]
E-cadherin Disrupts E-cadherin function Inhibits cell–cell adhesion Invasion and metastasis [13,53]
Exo70 Promotes correct exocyst localization Regulates exocytosis Invasion [61]
ERK1/2 Regulates MAPK signaling Promotes invasion Invasion [36,37]
MEK1/2 Regulates MAPK signaling Promotes invasion Invasion [23,36]
Sec3/8 Promotes MMP accumulation at invadopodia ECM degradation Invasion [60]
Src Unknown Proliferation and angiogenesis Transformation [49]
Abbreviations: ECM, extracellular matrix; MMP, matrix metalloproteinase.
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nase (ERK) phosphorylation and expression has been found in pan-
creatic cancer [31], and enhanced ERK phosphorylation correlates
with tumor progression in prostate cancer [32]. Increased MAPK
kinase (MEK) phosphorylation has been identiﬁed in colon cancer
[33] and in 74% of myeloblasts in acute myelogenous leukemia
[34].
IQGAP1 is a MAPK scaffold, which binds directly to and modu-
lates the functions of B-Raf [35], MEK [36] and ERK [37]. IQGAP1 is
required for activation of B-Raf by epidermal growth factor (EGF)
[35]. Similarly, IQGAP1 regulates the activation of MEK and ERK
in response to both EGF [36,37] and CD44 [38]. Thus, IQGAP1 is re-
quired for efﬁcient propagation of the MAPK cascade.
EGF differentially modulates the association of components of
the MAPK pathway with IQGAP1. Knockout of IQGAP1 from cells
renders B-Raf insensitive to EGF stimulation, while B-Raf associ-
ated with IQGAP1 has a much higher kinase activity compared
with free B-Raf [35]. It is unclear whether interacting with IQGAP1
enhances activation of B-Raf by EGF, or whether IQGAP1 preferen-
tially associates with B-Raf that has already been activated. Inter-
estingly, while ERK binds constitutively to IQGAP1 and the
binding is not sensitive to EGF, the interaction between IQGAP1
and MEK1 increases, while that with MEK2 decreases, following
EGF treatment [36]. This raises the possibility that IQGAP1 prefer-
entially activates the MEK1 signaling pathway. It has been sug-
gested that MEK1 promotes proliferation, while MEK2 promotes
differentiation [39]. Scaffold proteins serve as signaling nodes,
inﬂuencing signal intensity, time course and the speciﬁc cellular
response to an extracellular cue [40–42]. Thus, the scaffold func-
tions of IQGAP1 may modulate the cellular response to activation
of MAPK signaling, enhancing proliferation and reducing differen-
tiation. These changes could contribute to neoplasia.
Analogous to IQGAP1, siRNA-mediated knockdown of IQGAP3
suppresses ERK phosphorylation and signiﬁcantly reduces prolifer-
ation of Eph4 mammary epithelial cells [12]. Moreover, exogenous
expression of IQGAP3 induces a proliferative response, which is
blocked by the ERK inhibitor U0126. Thus, it appears that IQ-
GAP3-induced ERK activation may have a role in the regulation
of cellular proliferation.
4.2. b-Catenin-mediated transcription
b-Catenin, the central molecule in theWnt signaling pathway, is
integral to the control of cellular proliferation and cell–cell adhe-
sion, both of which are deregulated in malignancy [43,44]. Under
unstimulated conditions, b-catenin is held in a complex with ade-nomatous polyposis coli (APC) and axin, and is targeted for degra-
dation by casein kinase 1 (CK1) and glycogen synthase kinase-3b
(GSK-3b). In response to Wnt stimulation, CK1 and GSK-3b are
inhibited, and b-catenin accumulates in the cytoplasm from where
it translocates to the nucleus. Here, it promotes gene transcription
by binding to the T cell factor/lymphoid enhancer factor family of
transcription factors.
IQGAP1 binds directly to b-catenin. Overexpression of IQGAP1
enhances b-catenin nuclear localization and b-catenin-dependent
transcription in SW480 colon carcinoma and human bronchial epi-
thelial cells [45,46]. Furthermore, targeted disruption of the mur-
ine Iqgap2 gene results in increased expression of IQGAP1 in the
cytoplasm of hepatocytes, with a concomitant increase in cytoplas-
mic b-catenin, b-catenin activation and expression of cyclin D1 (a
nuclear target of the Wnt/b-catenin pathway) [47]. Taken together,
these ﬁndings suggest that IQGAP1 is an important regulator of b-
catenin function.
4.3. Cellular proliferation
Uncontrolled cellular proliferation is a fundamental characteris-
tic of neoplastic transformation. Recent studies have shown that
IQGAP proteins are important regulators of the proliferative re-
sponse. Overexpression of IQGAP1 increases proliferation of MCF-
7 cells, an effect dependent, at least in part, on increased active
Rac1 and Cdc42 [23]. Similarly, IQGAP1 is required for vascular
endothelial-derived growth factor (VEGF)-stimulated proliferation
as knockdown of IQGAP1 with siRNA abrogates proliferation of hu-
man umbilical vein [48] and aortic [49] endothelial cells. These
observations suggest that the IQGAP1 expression level directly dic-
tates the rate of cellular proliferation. Indeed, siRNA-induced IQ-
GAP1 knockdown signiﬁcantly reduces VEGF-stimulated
angiogenesis in vivo [49]. Furthermore, quercetin, an anti-oxida-
tive ﬂavonoid which is known to have strong anti-proliferative
properties [50], decreases IQGAP1 expression in HepG2 human
hepatocellular carcinoma (HCC) cells [51]. Interestingly, research
in the small intestine has shown that IQGAP3, but not IQGAP1 or
IQGAP2, is exclusively expressed in proliferating cells [12].
4.4. Cell–cell adhesion
Decreased tumor cell adherence at the primary site, increased
proteolytic degradation of surrounding tissue and enhanced cell
motility are required for cancer cells to metastasize. Loss of cell–
cell adhesion occurs as a result of reduced E-cadherin function,
but the precise molecular mechanisms underlying this effect are
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sion through homophilic associations with the extracellular do-
mains of E-cadherin on a neighboring cell. Importantly, IQGAP1
binds directly to E-cadherin [13,53] and overexpression of IQGAP1
reduces E-cadherin-mediated adhesion [53]. Similarly, transloca-
tion of IQGAP1 to cell–cell junctions attenuates E-cadherin func-
tion [13].
While no published studies have investigated the possible role
of mammalian IQGAP2 or IQGAP3 in cell–cell adhesion, a X. laevis
IQGAP2 homolog (XIQGAP2) localizes at cell–cell junctions in both
cultured Xenopus cells and embryos [54]. Suppression of XIQGAP2
expression by microinjection of morpholino antisense oligonucleo-
tides results in ectodermal lesions in mid-neurula stage embryos
due to loss of cell–cell adhesion [55]. These ﬁndings suggest that
XIQGAP2 expression positively regulates cell–cell adhesion during
early development. It remains to be determined whether IQGAP2
contributes to the maintenance of cell–cell adhesion in mammals.
4.5. Exocytosis
Tumor cell invasion across tissue boundaries is dependent on the
capacity of neoplastic cells to breach the basement membrane and
remodel the extracellular matrix (ECM), events which commonly
occur by proteolytic cleavage bymatrixmetalloproteinases (MMPs)
[56]. ActiveMMPs are delivered to the sites of contact between inva-
sive tumor cells and the ECM via dynamic cellular protrusions
known as invadopodia [57,58]. MMP accumulation at invadopodia
is thought to rely on vesicle exocytosis which, in turn, depends on
the successful targeting and tethering of vesicles to appropriate sites
on the cell membrane. Here, the exocyst, a multiprotein complex
consisting of eight subunits including Sec3, Sec8 and Exo70 [59], is
believed to play a pivotal role. Importantly, IQGAP1 binds Sec3,
Sec8 and Exo 70 [60,61], implicating IQGAP1 in the regulation of
exocytosis. Moreover, interaction between IQGAP1 and the exocyst
was shown to benecessary for invadopodia activity inMDA-MB-231
cells [60]. Interestingly, silencing IQGAP1 inhibits the invasion of
ovarian carcinoma HO-8910PM cells in vitro [62] and MCF-7 cells
in vitro and in vivo [23,63]. It is therefore tempting to speculate that
IQGAP1 mediates invasion, at least in part, by regulating exocytosis
and subsequent degradation of the ECM.
4.6. Cell migration
Most cancer deaths are caused by metastatic disease. The mech-
anism by which metastases develop remains to be fully elucidated,Table 2
Changes in Iqgap gene/mRNA expression level in neoplasms.B
Tissue comparison IQGAP Species Met
Cancer vs. normal Iqgap1 Human Arra
RT-P
Mouse Arra
Iqgap2 Human Arra
Aggressive vs. less aggressive cancerA Iqgap1 Human Arra
Mouse Arra
Iqgap2 Human Arra
Mouse Arra
Iqgap3 Human Arra
+, Increased expression; , decreased expression.
A Aggressive vs. less aggressive cancer is deﬁned by a decrease in long-term survivala,f, a
hormone therapyd.
B Only published studies with primary tissue are included. Data with cultured cell linbut it is agreed that cells must have both invasive and migratory
properties [64]. Many factors which are known to increase cell
migration in vitro have been shown to promote metastasis
in vivo [64]. IQGAP1 was originally characterized as regulator of
Rac1/Cdc42 signaling and actin dynamics [1,5–7], and much of
the early work on IQGAP1 focused on its role in regulating the
cytoskeleton. Consequently, IQGAP1 was observed to be an impor-
tant modulator of cell migration [63,65–67]. IQGAP1 cross-links
actin ﬁlaments [5,68], and localizes to the leading edge of migrat-
ing cells [63,66]. Increasing IQGAP1 expression in cells increases
the amount of active Cdc42 and promotes cell migration [63],
although other IQGAP1 binding partners, including actin, calmodu-
lin [69], and APC [66], are also likely to contribute to this effect.
siRNA-induced knockdown of IQGAP1 reduces the migration of
several human cell lines, such as MCF-7 [63] and U87MG human
glioblastoma cells [70]. In agreement with these studies, IQGAP1
is required for the induction of cell migration by ﬁbroblast growth
factor (FGF), VEGF and hyaluronan [38,48,71].
5. Role of IQGAP proteins in cancer
The work outlined above implicates the IQGAP proteins, partic-
ularly IQGAP1, in neoplasia by virtue of their cellular functions.
Nevertheless, it is important to note that much of these data were
obtained from cultured cell lines, and a critical reader may argue
that their relevance to cancer is largely circumstantial. In the fol-
lowing sections we discuss evidence derived from human neo-
plasms and mouse models of cancer, which more directly
identify the involvement of IQGAP1 and IQGAP2 in neoplastic
transformation and metastasis.
5.1. Genetic studies
The level of expression of IQGAP genes and mRNAs are fre-
quently altered in neoplasia. IQGAP1 has been proposed to be an
oncogene [23]. Consistent with this postulate, comparison of the
genetic proﬁles of tumors with those of normal tissue, and compar-
ison of more aggressive cancers with less aggressive neoplasms, re-
veals that the Iqgap1 gene and/or mRNA are overexpressed in all
analyses reported (Table 2). Increased expression of Iqgap1 has
been observed in several human neoplasms, including lung [72],
colorectal [73] and oligodendroglioma [72]. Analogous observa-
tions have been reported in mouse models (Table 2). Iqgap1 is
overexpressed in a genetically engineered mouse that recapitulates
the stages of human prostate cancer progression [74]. While nothod Neoplasm Expression change References
y Colorectal + [73]
Glioma + [97]
CR Glioma + [97]
Lung + [72]
y Prostate + [74]
y Colorectal + [78]
Prostate + [79]
y Glioma + [88]a
y Medulloblastoma + [98]b
Melanoma + [90]c
y Prostate  [77]d
y Prostate  [74]e
y Colorectal  [99]f
n increase in the likelihood of metastasisb,c,e or a decline in tumor responsiveness to
es have been omitted.
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tured cell lines. For example, the Iqgap1 gene is ampliﬁed in HSC39
and HSC40A gastric cancer cell lines [75]. This ampliﬁcation corre-
sponds to an increase in both IQGAP1 mRNA and protein, com-
pared with normal gastric cell lines, and an accumulation of
IQGAP1 protein at the cell membrane [75].
IQGAP2 has also generated several ‘‘hits” in genetic screens
comparing normal with neoplastic tissue (Table 2). The results,
however, are less unequivocal than those for IQGAP1. IQGAP2
expression is lost from 5/9 gastric cancer cell lines due to aberrant
methylation of the IQGAP2 promoter [76]. This abnormal methyl-
ation was also observed in 47% of primary gastric cancer tissues
(compared with 0% in normal tissue), and is signiﬁcantly associ-
ated with tumor invasion and a poor prognosis [76]. The inverse
correlation of Iqgap2 expression with cancer progression suggests
that IQGAP2 may be a tumor suppressor. This hypothesis is sup-
ported by studies which show reduced expression of the Iqgap2
gene in hormone-refractory prostate cancer [74,77]. However,
other reports contradict these ﬁndings as they observe overexpres-
sion of Iqgap2 in tissue from cancers of the colon [78] and prostate
[79] (Table 2). Thus, while there is evidence to suggest that Iqgap2
acts as a tumor suppressor, more thorough investigations are
required in order to verify this postulate and ascertain whether it
pertains only to selected neoplasms.
5.2. IQGAP protein expression and localization
The level of expression of IQGAP proteins is also altered in neo-
plasia (Table 3). Compared with normal tissue, IQGAP1 is overex-
pressed in colorectal carcinoma [80], breast cancer [23],
astrocytoma [81] and squamous cell carcinoma of the head and
neck [82]. Furthermore, IQGAP1 expression in aggressive ovarian
adenocarcinomas is higher than in adenomas or borderline tumors
[62], while a lack of IQGAP1 protein expression is associated with a
favorable prognosis in gastric cancer [83]. There is little published
on IQGAP2 protein expression in neoplasia. Only one paper, pub-
lished recently, addresses this topic. In this study, IQGAP2 expres-
sion is lost from 61% of human gastric carcinoma tissue, but is
detected in 100% of normal gastric mucosa [76]. This observation
is consistent with the postulated role for IQGAP2 as a tumor
suppressor.
In addition to increased expression, the subcellular localization
of IQGAP1 is altered in carcinoma. IQGAP1 is localized at the inva-
sive front of more aggressive colorectal [80] and ovarian [84] neo-
plasms. In the latter study, a diffuse expression pattern of IQGAP1
indicates a high histological grade and clinicopathological stage.
IQGAP1 overexpression and diffuse invasion pattern were signiﬁ-Table 3
Changes in IQGAP protein expression level in neoplasms.B
Tissue comparison IQGAP Species Method
Cancer vs. normal IQGAP1 Human IHC
MS
WB
WB
IQGAP2 Human IHC
Mouse IHC/WB
Aggressive vs. less aggressive cancerA IQGAP1 Human IHC
IHC/WB
+, Increased expression; , decreased expression.
Abbreviations: IHC, immunohistochemistry; WB, western blot; MS, mass spectrometry.
A Aggressive vs. less aggressive cancer is deﬁned by a decrease in long-term survivala
B Only published studies with primary tissue are included. Data with cultured cell lincantly associated with poor prognosis by multivariate analysis
[84]. Data from other groups support the premise that peripheral
localization of IQGAP1 is associated with more aggressive tumors.
For example, translocation of IQGAP1 from the cytoplasm to the
cell membrane correlates with dedifferentiation of gastric carci-
noma [85]. IQGAP1 is also implicated in endometrial adenocarci-
noma [86]. Compared with normal tissue, in well-differentiated
tumors, IQGAP1 disappears from cell adhesion sites, while E-cad-
herin is still present around cell boundaries [86]. However, in
poorly differentiated tumors, IQGAP1 and E-cadherin accumulate
in aggregates [86], suggesting that IQGAP1 and E-cadherin function
is disrupted in advanced, poorly differentiated tumors.
The connection between IQGAP1 and E-cadherin is also seen in
gastric cancers. In normal epithelium, IQGAP1 and E-cadherin are
localized to the cell–cell boundary [85]. However, IQGAP1 localizes
to the cytoplasm in intestinal-type tumors and to the cell periph-
ery in diffuse-type tumors [85]. These results are further supported
by fractionation data showing that in differentiated tumors IQ-
GAP1 is present in the soluble fraction and E-cadherin in the insol-
uble fraction, but both are insoluble in undifferentiated tumors
[85]. Consequently, it is thought that as tumor cells de-differenti-
ate, IQGAP1 moves from the cytoplasm to the cell periphery where
it disrupts E-cadherin function [85].
There is strong evidence to suggest that IQGAP1 expression can
serve as a biomarker for diagnosis of glioblastomas. In a rat model
of glioma, IQGAP1 expression is restricted to a subpopulation of
nestin-positive amplifying tumor cells in glioblastoma-like tumors,
but not oligodendroglioma-like tumors [87]. In human glioblas-
toma samples, IQGAP1 is a marker for nestin-positive cancer cells,
which appear to represent stem-like cancer progenitors [87]. In a
study to identify biomarkers of aggressive gliomas, IQGAP1 expres-
sion, along with insulin-like growth factor binding protein-2,
identiﬁes a subgroup of patients with grade III gliomas with poor
prognosis [88]. While normal glial tissue does not express IQGAP1,
cytoplasmic IQGAP1 staining is seen in 64% of gliomas [88].
Finally, outcome studies in other cancers are also beginning to
emerge. For example, increased Iqgap1 expression constitutes part
of a genetic signature that signiﬁcantly predicts the likelihood of
recurrence of colon cancer [89]. While it remains to be elucidated
if these ﬁndings are relevant to other tumors, these data suggest
that IQGAP1 may be useful in evaluation of patient prognosis.
5.3. IQGAP1 in metastasis
Genetic evidence using an in vivo scheme indicates a role for
Iqgap1 in metastasis. A screen for genes exhibiting altered expres-
sion in a mouse model of metastatic melanoma identiﬁed Iqgap1Neoplasm Expression change References
Colorectal + [80]
Squamous cell (Head and Neck) + [82]
Astrocytoma + [81]
Breast + [23]
Gastric  [76]
Liver  [47]
Gastric + [83]a
Glioma + [88]b
Lung + [100]c
Ovary + [84]d
Glioma + [87]e
,b,d or an increase in the likelihood of metastasisc,e.
es have been omitted.
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(from 10500 arrayed genes) that showed a >2.5-fold increase in
expression in metastatic cells [90]. The small number of genes
identiﬁed implies that increased expression of IQGAP1 and cal-
modulin are likely to be important in metastasis, rather than an
indirect result of the altered phenotype.
6. IQGAPs in tumorigenesis
As we have highlighted, accumulating evidence reveals that IQ-
GAP1 expression, both RNA and protein, is increased in several hu-
man malignancies. IQGAP2 concentration is also altered, but the
changes are less consistent and not as well-documented. These
studies are observational and do not indicate whether the reported
changes are a cause or simply a consequence of neoplastic trans-
formation. This question has been addressed in two recent publica-
tions, both of which provide strong evidence to suggest that
IQGAPs contribute to tumorigenesis. In the ﬁrst study, Jadeski
et al. [23] manipulated intracellular concentrations of IQGAP1 in
malignant MCF-7 cells. Speciﬁc knockdown of IQGAP1 by siRNA
signiﬁcantly reduces both serum-dependent proliferation and
anchorage-independent growth in soft agar. These in vitro data
strongly suggest that IQGAP1 is required for the transformed phe-
notype of MCF-7 cells, a postulate validated by in vivo analysis.
Subcutaneous injection into immunocompromised mice of MCF-7
cells overexpressing IQGAP1 gives rise to the formation of tumors
in 100% of mice and these tumors extensively invade skeletal mus-
cle [23]. Control MCF-7 cells form tumors in 60% of animals and do
not invade host tissue, whereas stable knockdown of IQGAP1 re-
sults in tumors in only 20% of mice and the complete abrogation
of invasion. Collectively these data strongly support the hypothesis
that IQGAP1 is an important component of breast cancer. Addi-
tional work is necessary to ascertain whether IQGAP1 functions
as an oncogene and is required for neoplastic transformation of
breast epithelial cells.
IQGAP2 is expressed predominantly in liver. Consistent with its
putative role as a tumor suppressor, targeted disruption of the
murine Iqgap2 gene results in the development of HCC [47]. The
neoplasia is restricted to the liver; non-hepatic tissue exhibits no
defects. Congruent with the evidence that it is an oncogene, IQ-
GAP1 is necessary for Iqgap2/ mice to develop HCC; interbreed-
ing Iqgap2/ mice into an Iqgap1-null background signiﬁcantly
decreases the incidence, size and aggressiveness of the tumors. IQ-
GAP1 expression is increased 9-fold in liver, but is not altered in
other organs [47]. While these ﬁndings need to be validated in hu-
man HCC, they strongly suggest that deregulation of IQGAP1 and
IQGAP2 may underlie the pathogenesis of this disease.7. Perspectives
IQGAP1 is frequently overexpressed in cancer while IQGAP2
expression is reduced in some neoplasms. The association of IQ-
GAP1 with its binding partners Cdc42, Rac1, E-cadherin, b-catenin,
components of the MAPK cascade and others may have a role in
transformation and metastasis. However, the speciﬁc interactions
that directly contribute to tumorigenesis have not been fully eluci-
dated. Moreover, it is not known at which of the multiple stages
that occur during the conversion of normal cells into malignant
derivatives IQGAP1 participates. The published data, albeit limited,
on IQGAP2 and IQGAP3 reveal that substantial differences exist
among the IQGAP family members with respect to tissue distribu-
tion, subcellular localization and binding partners. Additional work
is necessary to dissect out the biological implications of these dif-
ferences and determine the molecular mechanisms by which IQ-
GAP2 and IQGAP3 are likely to inﬂuence tumorigenesis.A fundamental question which remains to be answered is what
triggers overexpression of IQGAP1 and, in some neoplasms, loss of
IQGAP2? Several oncogenes and tumor suppressor genes, for
example Ras, B-Raf, p53 and APC [91,92], are mutated. Other onco-
genes, like the Rho GTPases, are not mutated, but are deregulated
during tumor progression [93]. A preponderance of evidence sug-
gests that, analogous to the Rho family, the Iqgap1 gene is ampli-
ﬁed in cancer and there is little indication of IQGAP1 mutation.
Genomic sequence analysis of Iqgap1 in 38 gastric cancers reveals
a missense nucleotide change at an allelic frequency of only 2.6%
(although other silent nucleotide changes were also observed)
[94]. There are no published reports describing mutation of the Iq-
gap2 or Iqgap3 genes in tumors. Further work is needed to ascertain
the molecular mechanisms by which Iqgap1 and Iqgap2 (and per-
haps Iqgap3) expression is altered in neoplasia.
The cumulative evidence strongly implicates the IQGAP pro-
teins in cancer. In addition to their altered levels in human neo-
plasms, IQGAPs appear to contribute to tumorigenesis. The
documented roles for many IQGAP binding proteins in multiple
stages of neoplastic transformation and metastasis, coupled with
the participation of IQGAPs in diverse signaling pathways that
are deregulated in cancer, combine to make IQGAP proteins con-
ceptually appealing chemotherapeutic targets.
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